BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 31852830)

  • 1. MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer.
    Khakoo S; Carter PD; Brown G; Valeri N; Picchia S; Bali MA; Shaikh R; Jones T; Begum R; Rana I; Wotherspoon A; Terlizzo M; von Loga K; Kalaitzaki E; Saffery C; Watkins D; Tait D; Chau I; Starling N; Hubank M; Cunningham D
    Clin Cancer Res; 2020 Jan; 26(1):183-192. PubMed ID: 31852830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study.
    Zhou J; Wang C; Lin G; Xiao Y; Jia W; Xiao G; Liu Q; Wu B; Wu A; Qiu H; Zhang F; Hu K; Xue H; Shen Z; Wang Z; Han J; Niu B; Xu Y; Yu Z; Yang L
    Clin Cancer Res; 2021 Jan; 27(1):301-310. PubMed ID: 33046514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study.
    Tie J; Cohen JD; Wang Y; Li L; Christie M; Simons K; Elsaleh H; Kosmider S; Wong R; Yip D; Lee M; Tran B; Rangiah D; Burge M; Goldstein D; Singh M; Skinner I; Faragher I; Croxford M; Bampton C; Haydon A; Jones IT; S Karapetis C; Price T; Schaefer MJ; Ptak J; Dobbyn L; Silliman N; Kinde I; Tomasetti C; Papadopoulos N; Kinzler K; Volgestein B; Gibbs P
    Gut; 2019 Apr; 68(4):663-671. PubMed ID: 29420226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
    Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
    PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer.
    McDuff SGR; Hardiman KM; Ulintz PJ; Parikh AR; Zheng H; Kim DW; Lennerz JK; Hazar-Rethinam M; Van Seventer EE; Fetter IJ; Nadres B; Eyler CE; Ryan DP; Weekes CD; Clark JW; Cusack JC; Goyal L; Zhu AX; Wo JY; Blaszkowsky LS; Allen J; Corcoran RB; Hong TS
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
    Tarazona N; Gimeno-Valiente F; Gambardella V; Zuñiga S; Rentero-Garrido P; Huerta M; Roselló S; Martinez-Ciarpaglini C; Carbonell-Asins JA; Carrasco F; Ferrer-Martínez A; Bruixola G; Fleitas T; Martín J; Tébar-Martínez R; Moro D; Castillo J; Espí A; Roda D; Cervantes A
    Ann Oncol; 2019 Nov; 30(11):1804-1812. PubMed ID: 31562764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
    Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
    Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
    Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
    Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic Value of Serum NPY Hypermethylation in Neoadjuvant Chemoradiotherapy for Rectal Cancer: Secondary Analysis of a Randomized Trial.
    Appelt AL; Andersen RF; Lindebjerg J; Jakobsen A
    Am J Clin Oncol; 2020 Jan; 43(1):9-13. PubMed ID: 31569168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence.
    Murahashi S; Akiyoshi T; Sano T; Fukunaga Y; Noda T; Ueno M; Zembutsu H
    Br J Cancer; 2020 Sep; 123(5):803-810. PubMed ID: 32565539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma.
    Wang X; Yu N; Cheng G; Zhang T; Wang J; Deng L; Li J; Zhao X; Xu Y; Yang P; Bai N; Li Y; Bi N
    Clin Transl Med; 2022 Nov; 12(11):e1116. PubMed ID: 36437506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
    Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence.
    Coombes RC; Page K; Salari R; Hastings RK; Armstrong A; Ahmed S; Ali S; Cleator S; Kenny L; Stebbing J; Rutherford M; Sethi H; Boydell A; Swenerton R; Fernandez-Garcia D; Gleason KLT; Goddard K; Guttery DS; Assaf ZJ; Wu HT; Natarajan P; Moore DA; Primrose L; Dashner S; Tin AS; Balcioglu M; Srinivasan R; Shchegrova SV; Olson A; Hafez D; Billings P; Aleshin A; Rehman F; Toghill BJ; Hills A; Louie MC; Lin CJ; Zimmermann BG; Shaw JA
    Clin Cancer Res; 2019 Jul; 25(14):4255-4263. PubMed ID: 30992300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
    Lee B; Lipton L; Cohen J; Tie J; Javed AA; Li L; Goldstein D; Burge M; Cooray P; Nagrial A; Tebbutt NC; Thomson B; Nikfarjam M; Harris M; Haydon A; Lawrence B; Tai DWM; Simons K; Lennon AM; Wolfgang CL; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Ann Oncol; 2019 Sep; 30(9):1472-1478. PubMed ID: 31250894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.
    Garcia-Murillas I; Chopra N; Comino-Méndez I; Beaney M; Tovey H; Cutts RJ; Swift C; Kriplani D; Afentakis M; Hrebien S; Walsh-Crestani G; Barry P; Johnston SRD; Ring A; Bliss J; Russell S; Evans A; Skene A; Wheatley D; Dowsett M; Smith IE; Turner NC
    JAMA Oncol; 2019 Oct; 5(10):1473-1478. PubMed ID: 31369045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.
    Tan L; Sandhu S; Lee RJ; Li J; Callahan J; Ftouni S; Dhomen N; Middlehurst P; Wallace A; Raleigh J; Hatzimihalis A; Henderson MA; Shackleton M; Haydon A; Mar V; Gyorki DE; Oudit D; Dawson MA; Hicks RJ; Lorigan P; McArthur GA; Marais R; Wong SQ; Dawson SJ
    Ann Oncol; 2019 May; 30(5):804-814. PubMed ID: 30838379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer.
    Schou JV; Larsen FO; Sørensen BS; Abrantes R; Boysen AK; Johansen JS; Jensen BV; Nielsen DL; Spindler KL
    Ann Oncol; 2018 Mar; 29(3):610-615. PubMed ID: 29253083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI Risk Stratification for Tumor Relapse in Rectal Cancer Achieving Pathological Complete Remission after Neoadjuvant Chemoradiation Therapy and Curative Resection.
    Kim H; Myoung S; Koom WS; Kim NK; Kim MJ; Ahn JB; Hur H; Lim JS
    PLoS One; 2016; 11(1):e0146235. PubMed ID: 26730717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
    Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
    Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.